62 results about "Diabetic kidney" patented technology

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders. The related pharmaceutical compositions and methods are also described. These compounds can be used in combination with comprising a therapeutic agent for lowering or controlling blood glucose level such as metformin or a thiazolidinedione.

The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.

The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and / or diabetic complications in human diabetic patient.

The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.

The invention belongs to the technical field of biology and particularly discloses selenium-rich bifidobacterium longum as well as a preparation method and application thereof. The selenium-rich bifidobacterium longum prepared by virtue of the preparation method can be applied to the preparation drugs or foods for delaying the progress of diabetes mellitus and particularly can be applied to the preparation of the drugs or the foods for improving the physical signs and metabolism conditions of diabetes mellitus, the insulin signal pathways of a diabetes mellitus model, the pathological change of livers, pancreas and kidneys of patients with diabetes mellitus and the levels of serum creatinine and blood urea nitrogen of diabetes mellitus and preventing renal complications or renal function damage of diabetes mellitus.

The invention provides berberine and panax notoginseng saponins and use of a composition using berberine and panax notoginseng saponins as effective components in preparing medicines for preventing and treating diabetes mellitus and complications thereof. The complications of diabetes mellitus are selected from diabetic cardiac abnormalities, diabetic renal lesions, diabetic retinopathy, diabetic peripheral neuropathy and diabetic vasculopathy.

The invention creatively provides miR-192 serving as a specificity biomarker for early diagnosis of a diabetic kidney disease and application of the MiR-192. The adopted technical scheme is as follows: application of the miR-192 in the serum to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the serum to diagnose the diabetic kidney disease; application of the miR-192 in the urine to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the urine to diagnose the diabetic kidney disease, a critical point of the miRNA-192 used for diagnosing the early diabetic kidney disease is provided, application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease, and application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease. A novel diagnosis means is provided for the clinical diagnosis of the diabetic kidney disease, and the miR-192 and the application of the miR-192 have certain potential clinical values for the adjuvant treatment and the course monitoring of the diabetic kidney disease (DKD).

The invention discloses a traditional Chinese medicine for treating diabetic kidney diseases, which belongs to the technical field of traditional Chinese medicines for treating diseases of urinary system. The invention aims to provide a traditional Chinese medicine for treating diseases of urinary system with remarkable effect and quick effectiveness. The traditional Chinese medicine is prepared by using medulla junci, pseudo-ginseng root, Chinese angelica, rehmannia root, lucid ganoderma, medlar, gordon euryale seed and the like as raw materials, and has the effects of strengthening body resistance and archaeus, tonifying qi, nourishing blood, nourishing yin, clearing heat, clearing damp, promoting diuresis, promoting blood circulation and removing blood stasis, and the advantages of obvious effect, and exact and quick effectiveness.

Methods and compositions are provided for diagnosing and treating a diabetic kidney disease (DKD) in an individual. In aspects of the methods, the levels of soluble circulating urokinase receptor (suPAR) in the blood are measured to predict a DKD, diagnose a DKD, or provide a prognosis pertaining to a DKD. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided.

The invention discloses a marker for detecting early diabetic nephropathy and an application methodof the marker. The application method includes the steps that a TTP is used as the diagnostic markerof diabetic nephropathy, TTP expression levels in blood and urine samples of a diabetic nephropathy patient are detected to be compared with normal values of a TTP expression level, and the illness state is diagnosed after difference analysis of the TTP expression level. According to the application method, early diabetic patients without clinical proteinuria but with actually developed diabetic kidney injury can be found, the diagnosis rate of early diabetic nephropathy is increased, and a basis for diagnosis of diabetic nephropathy is provided; and compared with traditional use of clinical symptoms, the advantage of early diagnosis is achieved, and compared with kidney puncture biopsy, the advantage of noninvasive diagnosis is achieved.

The invention relates to the medicinal application of NAM, specifically to application of NAM to preparation of drugs used for preventing and treating diabetic nephropathy and regulating blood pressure, belonging to the field of compounds. The experimental results of intervention of NAM in type 2 diabetes model mice prove NAM has obvious protective effect on diabetic kidneys and can alleviate therenal fibrosis, inflammations and oxidative stress in diabetic mice, and the protection effect is achieved independent of blood sugar reduction and weight improvement. Further, NAM can be used for preparing drugs for preventing and treating diabetic nephropathy and regulating blood pressure. The application of NAM in the invention provides a novel target and a novel idea for clinical prevention and treatment of diabetic nephropathy and improvement of renal lesions, and further proves that the improvement of renal oxidative stress plays an important role in the prevention and treatment of diabetic nephropathy.

The invention discloses an effective portion extracted from a conical hydrangea (Hydrangea paniculata sieb), and the preparation method of the effective portion comprises drug composite of the effective portion and the purpose of the effective portion and other drug composite which are used as drugs, and the effective portion is particularly applied in preparing drugs for preventing and / or treating kidney incompetence, high blood pressure and diabetic kidney disease.

The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease.

The invention provides a novel diabetic kidney lesion detection kit, which can identify early-stage patients more sensitively, accurately, simply, conveniently and noninvasively by being compared withtraditional indexes, and can be used as one of novel clinical auxiliary diagnosis means. According to the invention, a UPLC-ESI-MS / MS (ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry) method is used; nine novel serum metabolic markers that are related to early diabetic nephropathy and include hexadecanoic acid, delinoleic acid, azoxystrobin acid, lysophosphatidylcholine (20:4), piperidine, 6-methylmercaptopurine, 6-aminocaproic acid, L-hydrogenated orotic acid and cumin are screened out. Preliminary research data show that the group of metabolitescan diagnose patients with or without early diabetic kidney lesion through single or combined detection, a basis is provided for early intervention treatment of clinicians, and the occurrence of nephropathy at the final stage is reduced to the greatest extent.

The invention discloses a diabetic nephropathy screening method, model and system based on the AI technology. The diabetic nephropathy screening model based on the AI technology comprises a dynamic covariable and a Logistic regression calculation method, the dynamic covariable is K-dimensional data, and the K-dimensional data is data subjected to PCA dimension reduction processing. The diabetic nephropathy screening method and the system are established on the basis of the diabetic nephropathy screening model based on the AI technology, and evaluation result reference is provided for nephroticpatients by establishing the diabetic nephropathy screening model, method and system, so that the effect of early warning and preventing diabetic nephropathy is achieved. Besides, diabetic nephropathy auxiliary diagnosis reference can be provided for doctors.

A triple Tg (megsin / RAGE / iNOS-Tg) is constructed by crossing a megsin-Tg with an RAGE / iNOS-Tg. It is found out that this megsin / RAGE / iNOS-Tg suffers from the onset of remarkable diabetic kidney lesion at an early stage which has never been observed so far and shows various uniform lesion images such as glomerular enlargement. It is also found out that the animal showing these symptoms is useful as a model animal of diabetic nephropathy. That is to say, the disease model animal as described above overexpresses megsin gene, receptor for advanced glycation end product gene and inducible nitric oxide synthase gene and, therefore, suffers from renal dysfunction associated with glomerular disorders at an early stage.

The invention discloses a detection kit and a detection method for diabetic kidney diseases. The detection kit comprises a plate sealing film; a sealing the bag; an enzyme-labeled coating plate; a standard substance: 2700 ng / L; a standard substance diluent; an enzyme-labeled reagent; a sample diluent; a color developing agent solution A; a color developing agent solution B; a stop solution; and aconcentrated washing liquid. The invention relates to the technical field of diabetic nephropathy detection. The detection method is simple to operate, is less affected by metabolic disorders and hemodynamics, can detect diabetic nephropathy in the I phase, has extremely high sensitivity, and has great significance for clinical early diagnosis and discovery of diabetes.

The present invention discloses a pharmaceutical composition of ciclopirox olamine and its medical application. The pharmaceutical composition of ciclopirox olamine provided by the present invention contains ciclopirox olamine and a natural product compound (I) with a novel structure. Ciclopirox olamine and compound (Ⅰ) can protect the activity of antioxidant enzymes in rats, scavenge free radicals, and inhibit lipid peroxidation, suggesting that anti-oxidation is the mechanism by which ciclopirox olamine and compound (Ⅰ) protect the kidneys of DM rats one. After the combined use of ciclopirox olamine and compound (I), the blood lipid regulation and renal protection effects on rats with type 2 diabetes are further improved, and early application can effectively delay the occurrence and development of diabetic nephropathy, and can be developed into a treatment for diabetic nephropathy. The drug for pathological changes has outstanding substantive features and significant progress compared with the prior art.

The invention belongs to the technical field of pharmaceuticals, discloses application of a sarpogrelate containing pharmaceutical composition in treatment of diabetic nephropathy, and specifically discloses the application of a compound pharmaceutical composition taking sarpogrelate and 5-hydroxytryptamine synthesizing inhibitor as pharmaceutical active components in preparation of drugs for treating diabetic nephropathy. The test shows that gene silencing 5-HT synthetase and a 5-HT 2 receptor show good effect on inhibiting in-vitro culture and high glucose-induced oxidative stress of human renal mesangial cell strain, proinflammatory factor and chemotactic factor, and meanwhile, the gene silencing 5-HT synthetase system (Tph1 or AADC) and a 5HT 2 receptor are capable of greatly inhibiting high glucose-inducing effect and performing synergistic effect. With the adoption of the pharmaceutical composition, the diabetic nephropathy caused by high-fat feed feeding and streptozotocin induced diabetic nephropathy can be obviously treated; compared with simple prescription, the compound prescription is high in attenuation, and the lethal amount of mice orally taking the drug is obviouslyhalved.

The present disclosure relates to a method for controlling the differentiation of embryonic stem cells into adipocytes or kidney precursor cells by regulating SIRT1 (silent mating type information regulation 2 homolog; sirtuin 1) expression, the method, which controls the differentiation of embryonic stem cells into adipocytes by regulating SIRT1 expression, being capable of controlling the inhibition or promotion of adipocyte differentiation in accordance with the timing of a SIRT1 expression inhibitor treatment. Furthermore, kidney precursor cell differentiation can be regulated by a SIRT1 expression inhibitor or promoter treatment. Accordingly, a SIRT1 inhibitor can be selected to be used as an inhibitor or a therapeutic agent for obesity, diabetes accompanying obesity, and renal and metabolic diseases.

The invention discloses a traditional Chinese medicine for treating diabetic kidney disease, which includes following Chinese herbal medicines: poria, rice-paper plant pith, herba rorippae, akebia stem, radix euphorbiae kansui, Chinese lobelia herb, herba euphorbiae helioscopiae, mole cricket, hirsute shiny bugleweed herb, lilac pink herb, mealy fangji roots, armand clematis stem, okra roots, daylily, caulis et folium elaeagni viridis, rohdea japonica roots, pea, overground plant of Phyllodium pulchellum, villosulous veronicastrum herb or roots and sunflower stem pith. The traditional Chinesemedicine adopts the pure natural Chinese herbal medicines as the raw materials, treats both the symptoms and the roots, has definite curative effect, has no toxic or side effects, and allows a diseaseto be not liable to relapse.

The invention discloses a capsule for treating diabetic kidney damage for solving the problem in treatment of the diabetic kidney damage. The capsule is characterized in that a preparation method of the capsule comprises the following steps of: (1) carrying out steam distillation on gastrodia fruit, malva seed and Chinese taxillus twig to extract volatile oil for later use and reserving the dregs for later use; (2) smashing erythrina indica lam and parched rice sprout into fine powder for later use; (3) uniformly mixing fructus cannabis, magnolia amoena, trifoliate orange bark scrap, allium victorialis, catclaw buttercup root, Chinese starjasmine stem, cassia twig with the dregs obtained in the step (1), carrying out ethanol extraction twice, combining the two-time alcohol extract, filtering, recovering ethyl alcohol and concentrating into extract under reduced pressure; and (4) adding the extract obtained in the step (3) into the fine powder obtained in the step (2), uniformly mixing, drying at the temperature of 60 DEG C, smashing into fine powder, adding polysorbate-80, pelleting, drying, stabilizing size, spraying the volatile oil obtained in the step (1), uniformly mixing, and finally encapsulating. Proved by clinical experiments, the capsule for treating the diabetic kidney damage, disclosed by the invention, has the characteristics of good treatment effect and high safety and is worthy of clinical application and popularization.

The invention discloses a preparation method of phloretin-loaded soybean lecithin-chitosan nanoparticles, which comprises the following steps: dissolving chitosan in an acetic acid aqueous solution to prepare a chitosan mother solution; adding deionized water into the chitosan mother liquor to dilute the chitosan mother liquor to obtain a water phase; weighing phloretin, and dissolving phloretin in the soybean lecithin ethanol solution to serve as an ethanol phase; injecting the ethanol phase into the water phase under a magnetic stirring condition; after magnetic stirring, the pH is adjusted, and a phloretin-loaded soybean lecithin-chitosan nanoparticle solution is obtained. The soybean lecithin-chitosan nanoparticle solution loaded with phloretin or the phloretin nanoparticles prepared from the soybean lecithin-chitosan nanoparticle solution loaded with phloretin can be used for preparing drugs for treating diabetic kidney.

This invention relates to a new method of treating diabetes in a population of subjects that is characterised as having severe insulin-resistant diabetes. This population is typically obese, insulin resistance and hyperglycemic and has an elevated risk of diabetic kidney disease. The compound of formula I has been found to treat high body weight, insulin resistance and hyperglycemia and to have a positive effect on microvascular perfusion in glomeruli and so is particularly suited for the treatment of this patient group.

The invention relates to the field of kidney disease differential diagnosis, in particular to a diabetic nephropathy and non-diabetic kidney disease differential diagnosis prediction model and a construction method. By analyzing clinical and pathological characteristics of patients with type 2 diabetes, factors which have great influence on differential diagnosis results are selected, and a column diagram form is adopted, so the method is simple, clear, popular, easy to understand and convenient for clinical operation. According to the kit, the probability that the patients are subjected to renal needle biopsy pathological diagnosis to be non-diabetic kidney diseases (NDRD) and diabetic nephropathy combined non-diabetic kidney diseases (MIX) can be judged according to initial detection data of the type 2 diabetes patients, and differential diagnosis of the diabetic nephropathy and the non-diabetic kidney diseases in the type 2 diabetes patients is achieved. By means of the probability prediction method, clinical doctors can evaluate the kidney biopsy risk income ratio of the type 2 diabetes kidney injury patient, and meanwhile reference is provided for workers of medical institutions without the kidney biopsy technology.

The invention discloses a pharmaceutical composition of chlorpropamide and its medical application. The pharmaceutical composition of chlorpropamide provided by the invention contains chlorpropamide and a kind of The novel natural product compound (Ⅰ), chlorpropamide, compound (Ⅰ) can protect the activity of antioxidant enzymes in rats, scavenge free radicals, and inhibit lipid peroxidation, suggesting that antioxidants are chlorpropamide, One of the mechanisms by which compound (I) protects the kidneys of DM rats. After the combined use of chlorpropamide and compound (I), the blood lipid regulation effect and renal protection effect on rats with type 2 diabetes were further improved. Early application can effectively delay the occurrence and development of diabetic nephropathy, and can be developed into a treatment for diabetic nephropathy. The drug for pathological changes has outstanding substantive features and significant progress compared with the prior art.

The invention relates to an application of ginsenoside compound K or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating diabetic kidney diseases.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

The invention discloses novel application of an FOXO1 selective inhibitor AS1842856. The novel application of the AS1842856 (formula I) provided by the invention is the application of the AS1842856 inpreparation of a medicine for preventing and / or treating the diabetic kidney disease. Pharmacodynamic experiments in the invention prove that: by applying AS1842856, the levels of serum creatinine and blood urea nitrogen in diabetic kidney disease injury can be obviously reduced; infiltration of kidney tissue macrophages is inhibited; and the application prospect in the aspect of kidney protection is good.